OA09463A - "Nouveaux sels de métaux bivalents de l'acide N, N-DI(carboxyméthyl) amino-2 cyano-3 carboxyméthyl-4 carboxy-5 thiophène leur procédé de préparation et les compositions pharmaceutiques les renfermant". - Google Patents

"Nouveaux sels de métaux bivalents de l'acide N, N-DI(carboxyméthyl) amino-2 cyano-3 carboxyméthyl-4 carboxy-5 thiophène leur procédé de préparation et les compositions pharmaceutiques les renfermant".

Info

Publication number
OA09463A
OA09463A OA59850A OA59850A OA09463A OA 09463 A OA09463 A OA 09463A OA 59850 A OA59850 A OA 59850A OA 59850 A OA59850 A OA 59850A OA 09463 A OA09463 A OA 09463A
Authority
OA
OAPI
Prior art keywords
carboxymethyl
cyano
amino
metal salts
thiophene
Prior art date
Application number
OA59850A
Other languages
English (en)
French (fr)
Inventor
Wierzbicki Michel
Bonnet Jacqueline
Brisset Martine
Tsouderos Yannis
Original Assignee
Adir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adir filed Critical Adir
Publication of OA09463A publication Critical patent/OA09463A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
OA59850A 1989-09-01 1990-08-31 "Nouveaux sels de métaux bivalents de l'acide N, N-DI(carboxyméthyl) amino-2 cyano-3 carboxyméthyl-4 carboxy-5 thiophène leur procédé de préparation et les compositions pharmaceutiques les renfermant". OA09463A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8911475A FR2651497B1 (fr) 1989-09-01 1989-09-01 Nouveaux sels de metaux bivalents de l'acide n, n-di (carboxymethyl)amino-2 cyano-3 carboxymethyl-4 carboxy-5 thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant.

Publications (1)

Publication Number Publication Date
OA09463A true OA09463A (fr) 1992-11-15

Family

ID=9385063

Family Applications (1)

Application Number Title Priority Date Filing Date
OA59850A OA09463A (fr) 1989-09-01 1990-08-31 "Nouveaux sels de métaux bivalents de l'acide N, N-DI(carboxyméthyl) amino-2 cyano-3 carboxyméthyl-4 carboxy-5 thiophène leur procédé de préparation et les compositions pharmaceutiques les renfermant".

Country Status (18)

Country Link
US (1) US5128367A (de)
EP (1) EP0415850B1 (de)
JP (1) JPH0692386B2 (de)
AT (1) ATE100093T1 (de)
AU (1) AU624022B2 (de)
CA (1) CA2024419C (de)
DE (2) DE69005950T2 (de)
DK (1) DK0415850T3 (de)
ES (1) ES2062450T4 (de)
FR (1) FR2651497B1 (de)
HK (1) HK57097A (de)
IE (1) IE65157B1 (de)
LU (1) LU91125I2 (de)
NL (1) NL300168I2 (de)
NZ (1) NZ234770A (de)
OA (1) OA09463A (de)
PT (1) PT95184B (de)
ZA (1) ZA906716B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7404967B2 (en) * 1994-12-21 2008-07-29 Cosmederm, Inc. Topical product formulations containing strontium for reducing skin irritation
FR2749759B1 (fr) * 1996-06-17 1999-11-26 Adir Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose
FR2844795B1 (fr) 2002-09-24 2004-10-22 Servier Lab Nouveau procede de synthese industriel du ranelate de strontium et de ses hydrates
FR2844797B1 (fr) 2002-09-24 2004-10-22 Servier Lab Nouveau procede de synthese industriel des tetraesters de l'acide 5-[bis (carboxymethyl)]-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates
FR2844796A1 (fr) * 2002-09-24 2004-03-26 Servier Lab Nouveau procede de synthese industrielle du diester methylique de l'acide 5-amino-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates
FR2846558B1 (fr) * 2002-11-05 2006-07-14 Servier Lab Utilisation du sel distrontique de l'acide 2-n,n-di(carboxymethyl)amino-3-cyano-4-carboxymethyl- thiophene-5-carboxylique pour l'obtention de medicaments destines au traitement des douleurs gastro-duodenales
ES2394782T3 (es) * 2003-05-07 2013-02-05 Osteologix A/S Composición con estroncio y vitamina D para la profilaxis y/o tratamiento de afecciones de cartílagos y/o huesos
WO2005082385A1 (en) * 2004-02-26 2005-09-09 Osteologix A/S Strontium-containing compounds for use in the prevention or treatment of necrotic bone conditions
PL1622629T3 (pl) * 2003-05-07 2013-12-31 Osteologix As Kompozycja do kontrolowanego uwalniania zawierająca sól strontu
PL1745791T3 (pl) * 2003-05-07 2013-11-29 Osteologix As Leczenie chorób chrząstki/kości za pomocą rozpuszczalnych w wodzie soli strontu
US6905723B2 (en) * 2003-05-30 2005-06-14 Depuy Products, Inc. Strontium-substituted apatite coating
US20050085531A1 (en) * 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
AU2005240257B2 (en) 2004-05-06 2011-11-24 Osteologix A/S High yield and rapid syntheses methods for producing metallo-organic salts
JP5070046B2 (ja) 2004-06-25 2012-11-07 モクワロ エスペーエフ エス．アー． ストロンチウムおよびビタミンｄを含む組成物およびその使用
FR2875807B1 (fr) * 2004-09-30 2006-11-17 Servier Lab Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
CN100391955C (zh) * 2005-04-30 2008-06-04 河北医科大学 一种雷尼酸锶中间体的合成方法
EP1928855A2 (de) * 2005-08-19 2008-06-11 Glenmark Pharmaceuticals Limited Verfahren zur darstellung von strontiumranelat
FR2899895B1 (fr) * 2006-04-12 2010-09-17 Servier Lab Nouveaux sels de strontium d'acides sulfoniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20070292529A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating osteoporotic conditions
US20070292535A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating arthritic and or osteoporitic conditions
CN101229154B (zh) * 2007-01-26 2010-05-12 鲁南制药集团股份有限公司 治疗骨质疏松的药物组合物
FR2921367B1 (fr) * 2007-09-26 2009-10-30 Servier Lab Nouveau procede de synthese du ranelate de strontium et de ses hydrates
US20120123131A1 (en) * 2008-08-22 2012-05-17 Koilpillai Joseph Prabahar Process for the preparation of strontium ranelate
WO2010034806A1 (en) 2008-09-29 2010-04-01 Ratiopharm Gmbh Anhydrate and hydrate forms of strontium ranelate
CN101747316B (zh) * 2008-12-12 2013-09-25 重庆医药工业研究院有限责任公司 高纯度的雷奈酸锶及其制备方法
WO2010117346A2 (en) 2009-04-10 2010-10-14 Mahmut Bilgic Stable pharmaceutical compositions with high bioavailibility
FR2953139B1 (fr) 2009-11-27 2012-04-13 Servier Lab Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine
CN101775002B (zh) * 2009-12-23 2015-07-15 浙江华海药业股份有限公司 一种制备雷尼酸锶的方法
HU228820B1 (en) 2010-01-14 2013-05-28 Richter Gedeon Nyrt Process for the preparation of distrontium ranelate
IT1398542B1 (it) 2010-03-05 2013-03-01 Chemelectiva S R L Processo per la preparazione di un polimorfo
WO2011110597A1 (de) 2010-03-11 2011-09-15 Azad Pharmaceutical Ingredients Ag Verfahren zur herstellung von strontiumranelat
WO2011124992A1 (en) 2010-03-24 2011-10-13 Actavis Group Ptc Ehf Substantially pure strontium ranelate
CN102241663B (zh) * 2010-05-10 2013-02-13 山东方明药业集团股份有限公司 一种雷奈酸锶八水合物的制备方法
WO2012046251A2 (en) * 2010-10-08 2012-04-12 Glenmark Generics Limited Novel form of ranelic acid
CN102180864B (zh) * 2011-03-28 2012-12-12 中国药科大学 一种雷尼酸锶的制备方法
CZ2011320A3 (cs) 2011-05-30 2012-12-12 Zentiva, K.S. Stabilní krystalická forma X stroncium ranelátu
EP2530068A1 (de) 2011-05-31 2012-12-05 Lacer, S.A. Neue Strontiumsalze, deren Synthese und Verwendung bei der Behandlung von Osteoporose
WO2013013003A1 (en) 2011-07-21 2013-01-24 Emory University Methods for treating inflamatory conditions and states, and cancers by antagonizing nf-kb activation
CN102503931A (zh) * 2011-09-20 2012-06-20 浙江华海药业股份有限公司 一种雷尼酸锶晶形h的制备方法
WO2013113319A1 (en) 2012-01-31 2013-08-08 Pharmathen S.A. Process for the preparation of strontium ranelate, intermediate or hydrates thereof
EP2641905A1 (de) 2012-03-23 2013-09-25 Urquima S.A. Feste Formen von Strontiumranelat und Verfahren zu ihrer Herstellung
US8569514B1 (en) 2012-05-17 2013-10-29 Divi's Laboratories, Ltd. Process for the preparation of strontium ranelate
CN103804345B (zh) * 2013-09-06 2017-03-15 精华制药集团股份有限公司 一种用hplc法中控制备高纯度雷尼酸锶的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3905577A1 (de) * 1989-02-23 1990-08-30 Basf Ag Diaminothiophene

Also Published As

Publication number Publication date
US5128367A (en) 1992-07-07
ES2062450T3 (es) 1994-12-16
PT95184A (pt) 1991-05-22
ATE100093T1 (de) 1994-01-15
HK57097A (en) 1997-05-09
ZA906716B (en) 1991-06-26
PT95184B (pt) 1997-06-30
CA2024419C (fr) 1999-07-20
JPH0692386B2 (ja) 1994-11-16
AU6203390A (en) 1991-03-07
FR2651497B1 (fr) 1991-10-25
NL300168I1 (nl) 2005-03-01
IE903162A1 (en) 1991-03-13
EP0415850A1 (de) 1991-03-06
NZ234770A (en) 1991-11-26
CA2024419A1 (fr) 1991-03-02
FR2651497A1 (fr) 1991-03-08
IE65157B1 (en) 1995-10-04
EP0415850B1 (de) 1994-01-12
DE69005950T2 (de) 1994-07-21
DE69005950D1 (de) 1994-02-24
NL300168I2 (nl) 2005-03-01
ES2062450T4 (es) 2011-12-29
DE122005000001I1 (de) 2005-05-12
DE122005000001I2 (de) 2006-02-09
JPH03169876A (ja) 1991-07-23
DK0415850T3 (da) 1994-03-21
LU91125I2 (fr) 2005-02-15
AU624022B2 (en) 1992-05-28

Similar Documents

Publication Publication Date Title
OA09463A (fr) "Nouveaux sels de métaux bivalents de l'acide N, N-DI(carboxyméthyl) amino-2 cyano-3 carboxyméthyl-4 carboxy-5 thiophène leur procédé de préparation et les compositions pharmaceutiques les renfermant".
DK20488A (da) Farmaceutiske praeparater med forlaenget afgivelse
DE69738948D1 (de) Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten
MX163955B (es) Composicion farmaceutica de dihidrocodeina e ibuprofen
ATE175348T1 (de) L - deprenyl zur behandlung von makulärer degeneration
ATE143261T1 (de) Zusammensetzung zur behandlung entzündlicher darmerkrankungen
DK164441C (da) Anvendelse af et piperidinderivat til fremstilling af et farmaceutisk praeparat til behandling af smertetilstande
DE69025271D1 (de) Pharmazeutische Zubereitungen mit verzögerter Freisetzung zur Behandlung periodontaler Erkrankungen
ATE125706T1 (de) Diphosphonate enthaltende pharmazeutische zusammensetzungen zur behandlung von arthrosis.
EP0376251A3 (en) An anticoagulant substance obtained from urine
BG49827A3 (en) Method for preparing a clean byologic active recombinative human colonium stimulating factor
ES2044170T3 (es) Sal de estroncio, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen.
FR2612775B1 (fr) Compositions pour la prevention et le traitement de la degenerescence cutanee
ES2054089T3 (es) Formulaciones orales liquidas.
FR2614203B1 (fr) Composition pharmaceutique pour le traitement des maladies de la peau et son procede de preparation.
ES2060440T3 (es) Derivados de acidos 1,4-dihidropiridin-dicarboxilicos aril-quinolil substituidos, procedimiento para su fabricacion y su uso en medicamentos.
FR2612774B1 (fr) Compositions cosmetiques et pharmaceutiques, utilisees pour traiter le processus de l'alopecie androgenogenetique, contenant de l'acide azelaique
FR2564831B3 (fr) Nouveaux derives des acides aroyl- ou hydroaroyl n-alcoyl pyrrolyl-2 carboxyliques et nouvelles compositions pharmaceutiques a action immuno-suppressive
TNSN89135A1 (fr) Procede d'obtention de nouvelles compositions et nouveaux produits pharmaceutiques assurant la regineration des leucocytes et leur emploi dans le traitement du syndrome immuno-deficitaire
SE8802323D0 (sv) 8alfa-acylaminoergoline, its preparation and pharmaceutical compositions containing it
IT8448370A0 (it) Citrato trisodico utilizzabile nella cura delle malattie artriticoreumatiche
IT1246050B (it) Impiego dell'eptastigmina nella terapia dell'ictus cerebrale.
RU93048568A (ru) 14,14,14-трифтор-12-оксатетрадекановая кислота, липидный ингибитор вируса иммунодефицита человека